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Summary
Here, we describe the development of a method that
exploits bacteriophage D29 as a lysis agent for effi-
cient DNA extraction from low numbers of mycobac-
terial cells. This method (Actiphage) used in
combination with PCR achieved rapid and sensitive
(LOD ≤ 10 cell ml1) detection and identification of
viable, pathogenic mycobacteria in blood samples
within 6 h. We demonstrate that mycobacteriophage
D29 can be used to detect a range of mycobacteria
from clinical blood samples including both Mycobac-
terium tuberculosis complex and Mycobacterium
avium subsp. paratuberculosis without the need for
culture and confirms our earlier observations that a
low-level bacteraemia is associated with these infec-
tions in cattle. In a study of M. bovis-infected cattle
(n = 41), the sensitivity of the Actiphage method
was 95 % (95 % CI; 0.84–0.99) and specificity was
100 % (95% CI; 0.92–1). We further used Actiphage
to demonstrate viable Mycobacterium avium subsp.
paratuberculosis is present in the blood of Johne’s
infected cattle. This method provides a revolutionary
new tool for the study of infections caused by these
difficult to grow pathogens.
Introduction
Mycobacteria are responsible for a wide range of dis-
eases in humans and animals. Mycobacterium tuberculo-
sis and Mycobacterium bovis cause tuberculosis (TB)
predominantly in humans and cattle, respectively,
although it is known that M. bovis can infect a wide
range of other animals including humans. Mycobac-
terium avium subsp. paratuberculosis (MAP) causes
Johne’s disease, a severe wasting disease in ruminants.
This disease is endemic in many commercial ruminant
herds worldwide (Groenendaal and Zagmutt, 2008) and
is recognized as causing significant economic losses to
the dairy industry. MAP has also been associated with
development of Crohn’s disease in humans (Naser
et al., 2014), although a causative link has yet to be con-
clusively proven.
Bacteria belonging to the genus Mycobacterium are
typically split into fast-growing and slow-growing types,
with the fast-growing bacteria being able to form colonies
within 7 days of incubation. In contrast, the slow grow-
ers, which typically include the pathogenic species, take
more than 7 days to form visible colonies (Wayne and
Kubica, 1986; Chacon et al., 2004) and this slow-grow-
ing attribute presents the biggest barrier when studying
infections caused by these bacteria. For instance culture
of M. bovis, MAP and M. tuberculosis require incubation
times ranging from weeks to months (Plain et al., 2015).
Culturing these organisms requires complex media and
specialist equipment and is therefore costly in terms of
time and reagents. In addition, these bacteria typically
exhibit a low plating efficiency, where only a proportion
of viable cells in a culture will grow into colonies; thus,
culture is not always a reliable way to detect low num-
bers of cells present in a sample (Messelhausser et al.,
2012; Fawzy et al., 2015). This problem is exacerbated
by the need to treat clinical samples with harsh chemi-
cals to inactivate contaminating microbes that will over-
grow samples during the long incubation periods, but
also reduces the viable population of mycobacteria
(Grant et al., 2003; Medeiros et al., 2012). Despite these
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limitations, culture-based methods are still considered to
be the gold standard for diagnostic purposes (Raffo
et al., 2017), even though it may not be as sensitive as
other diagnostic tests for detecting infection.
These difficulties mean that alternative, more rapid
detection methods for mycobacteria are often used. PCR
has proven to be a powerful tool for the specific detec-
tion of mycobacterial signature DNA sequences from a
variety of sample matrices (Dinnes et al., 2007; Priyadar-
shini et al., 2017), and most recently loop-mediated
isothermal amplification (LAMP) methods have been
successfully developed for the specific detection of MAP
(Punati et al., 2019). However, when used as a diagnos-
tic test, efficient release of DNA is crucial for the success
of any PCR or nucleic acid-based method, especially
when this is being used to quantify the number of cells
present in a sample. Mycobacteria have mycolic acid-rich
cell walls which are physically robust and difficult to rup-
ture, and this can adversely affect the sensitivity of PCR-
based detection methods (Vandeventer et al., 2011). Inhi-
bitors present in different sample matrices can also affect
PCR sensitivity, especially when the sample originates
from clinical specimens such as whole blood. Another
problem is that standard PCR detects all DNA and there-
fore does not discriminate between material originating
from live or dead cells (Yang and Rothman, 2004), which
limits its use to monitor disease clearance or treatment.
Advances are being made with electrochemical-based
sensors for human diagnostics, which can be performed
independently of culture, but are not currently developed
for use in animals (Golichenari et al., 2019). Currently,
there is no routine, highly sensitive method that combines
the specificity and rapidity of PCR with the live/dead dif-
ferentiation of culture.
Bacteriophage (phage) are viruses that are natural
predators of bacteria, and phage-based detection meth-
ods for mycobacteria were first described for the detec-
tion of M. tuberculosis in humans (Rees and Botsaris,
2012). One such assay has been termed phage amplifi-
cation and results in the formation of plaques in a lawn
of the fast-growing non-pathogen M. smegmatis (Stewart
et al., 1998). We previously showed that the DNA
released from the mycobacterial cells detected at the
end of the assay could be extracted from the plaques
and used as a template for amplification of mycobacte-
rial signature sequences (phage-PCR) (Stanley et al.,
2007). In further studies, phage-PCR or phage-RPA (re-
combinase polymerase amplification) has been used to
detect different mycobacterial pathogens, including mem-
bers of the M. tuberculosis complex group of organisms,
as well as MAP, in blood and milk samples from natu-
rally infected animals (Stanley et al., 2007; Botsaris
et al., 2010; Swift et al., 2013; Swift et al., 2016a). In
these studies, identification and enumeration of slow-
growing mycobacteria was possible within 2 days. How-
ever, the method is laborious, requires the overnight
incubation of bacterial culture plates and is not suitable
for high-throughput testing. A specific problem is the
mechanical handling and transfer of materials into the
different types of containers required for the different
stages of the assay, which can lead to loss of sample
and reduced sensitivity of detection (Swift et al., 2016a).
Phage commonly encode enzymes to efficiently break
open cells to release the progeny phage at the end of
their replication cycle (Rodriguez-Rubio et al., 2016). It
was hypothesized that a new method could be devel-
oped to detect low numbers of mycobacteria by utilizing
phage to efficiently lyse the host cells in a liquid sample
and then using DNA amplification methods to sensitively
detect the DNA released from these cells. This would
remove the requirement to amplify the detection event
by using lawns of fast-growing mycobacteria. In addition,
this approach would be simpler, faster and should
increase sensitivity of the original phage-PCR method as
there is less opportunity for sample loss. Here, we pre-
sent the development of a rapid detection method
(Actiphage) that uses phage to lyse the mycobacteria
cells in a liquid system. The sensitivity of the new
method compared with phage-PCR was then determined
using clinical blood samples.
Results
Determining the eclipse phase of bacteriophage D29
Phage D29 is a well-studied and characterized mycobac-
teriophage with a broad-host range that is capable of
infecting wide range of pathogenic and non-pathogenic
mycobacteria (Dedrick et al., 2017). The proposed basis
of the new Actiphage method is that viable mycobacte-
ria release DNA during the lysis event that occurs at the
end of the D29 lytic cycle, and this DNA can be detected
by PCR to identify the cell type present in the sample.
David et al. (1980) showed that the growth rate of D29
is related to the growth rate of the host cells; therefore, it
was important to determine the time required for D29 to
complete its replication period and induce bacterial cell
lysis for different hosts under the conditions used for the
phage assays. This was achieved using a modification
of the phage amplification method to determine the
length of the eclipse phase (time between infection and
bacterial cell lysis) for different types of mycobacteria.
The results (Fig. S1) showed that new phage particles
began to be released from infected M. smegmatis and
M. bovis BCG cells after approximately 120 min. The
eclipse phase for MAP was longer with phage particles
released after 135 min. From this, it was determined that
after addition of phage, and allowing for asynchronous
infection events, an additional 45 min of incubation
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(180 min total incubation) would be sufficient to allow
D29 to complete its replication cycle and fully release
the genomic DNA from all of the different types of
mycobacterial cells present in a sample.
Establishment of the principles of the Actiphage
method
The results showed that following lysis with the phage,
DNA released from both MAP strains used was detected
(Fig. 1). However, a small amount of PCR product was
detected in the phage-negative control indicating that
some DNA was being detected due to heat lysis of intact
cells during PCR (Fig. 1, lane 3). While this experiment
confirmed that the host DNA was preserved sufficiently
in a liquid phage lysate to allow later detection by PCR,
it suggested that centrifugation was not an effective
method to remove any remaining intact cells. To resolve
this problem, after incubation with the phage the mixture
containing lysed cells and phage (100 µl) was passed
through a 0.22-µm filter to remove any remaining intact
cells from the lysate and the DNA cleaned and concen-
trated as before. Using this separation method, PCR
amplification of the signature sequences now only
occurred in the samples to which the phage had been
added, indicating that the release of DNA was due to
phage replication in the viable cells (Fig. 1, lane 4).
Determining the Limit of Detection (LOD) of the
Actiphage method in blood
To determine whether the Actiphage method was cap-
able of detecting mycobacteria recovered from PBMCs,
cultures were diluted and samples ranging from 104 to
0 pfu ml-1 (rapid enumeration of cell number was per-
formed using the phage amplification assay; 2.3). In this
experiment, a recent clinical isolate of M. bovis
recovered from an infected badger was used to repre-
sent a strain that had not been continuously passaged in
the laboratory was included in the test set as well as lab-
oratory strains of MAP and M. bovis BCG. The diluted
samples of bacteria were mixed with whole sheep blood
for 4 h to allow internalization of the mycobacteria within
PBMCs (Bower et al., 2010), and then, PBMCs were puri-
fied using ficoll gradients. The purified PBMCs were
resuspended in modified 7H9 media which results in lysis
of the PBMCs and release of any intracellular mycobacte-
ria into the media (Swift et al., 2016b; Donnellan et al.,
2017). Samples were tested using either the phage ampli-
fication or the Actiphage method. The results (Table 1)
showed that the Actiphage method was able to detect
fewer cells than the original phage amplification method
for MAP and the clinical isolate of M. bovis, with a LOD
of < 10 cells. For the M. bovis BCG strain, the detection
limit was the same for both methods.
Improved sensitivity for detection of M. tuberculosis
complex in naturally infected SICCT-positive animals
In our previous paper, we reported that 66 % of blood
samples from Single Intradermal Comparative Cervical
Tuberculin (SICCT) test-positive cattle had detectable
levels of MTB complex in their blood using phage-RPA
(Swift et al., 2016a). A second blood sample from these
SICCT-positive cattle was tested in parallel using the
Actiphage method and now DNA from MTB complex
bacteria was detected in 95 % (39/41) of the samples
(Fig. 2). There was a 100% correlation between the
phage negatives, but when assessed overall, these data
demonstrate a weak positive correlation between the
original phage assay and the Actiphage assay
(r = 0.31; 95% CI: 0.01–0.57), where significantly more
MTB complex bacteria were detected using Actiphage
(P < 0.001). These SICCT-positive animals had been
Fig. 1. Detection of MAP DNA with and without phage lysis. The effect of centrifugation (Lanes 2 and 3) and filtration (Lanes 4 and 5) on the
PCR amplification of signature IS900 sequences of MAP. Lane 1 is the molecular marker (100 bp ladder). In lanes 2 and 4, the MAP cells were
lysed using phage, and in lanes 3 and 5, no phage was added to the sample. Lane 6 is the no template control.
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classified post-mortem as either Visible (VL) or non-visi-
ble lesion (NVL), and the data showed that the
Actiphage method detected MTB complex bacteria in
the blood of all (n = 13) of the VL animals and 93 %
(26/28) of the NVL animals. In comparison, the original
phage-RPA method detected only 11/13 and 16/28 for
the VL and NVL groups respectively. Interestingly, both
of the animals that gave a negative result using the
Actiphage method were also negative when tested
using the phage-RPA method. Results for blood samples
from a negative control group (45 animals) all gave neg-
ative results using both methods, indicating that the
increased detection rate achieved using the Actiphage
method was not due to decreased specificity. Using the
SICCT status as a comparator, the Actiphage phage
assay delivered a sensitivity of 95 % (95 % CI; 0.84–
0.99) and specificity of 100 % (95 % CI; 0.92–1).
Comparison of Actiphage with phage-PCR detection of
MAP in cattle blood
We have previously shown that phage-PCR can be used
to detect MAP in the blood of naturally infected cattle
(Swift et al., 2013). To confirm that the new Actiphage
method was also able to detect MAP in blood, samples
were obtained from experimentally infected cattle that
were part of an on-going study which included 15 ani-
mals that had been orally inoculated with MAP F13 and
also from eight matched, uninfected negative control ani-
mals. The blood samples were taken 9 months post-in-
fection for analysis by commercial ELISA (IDEXX) and
by both the Actiphage method and the phage-PCR
method. For the phage assays, PBMCs were purified
from 2 ml of whole blood which were then split into two
parallel samples after they had been resuspended in
modified 7H9 media to release any intracellular
mycobacteria.
Culture of intestinal tissues was carried out at
necropsy to provide evidence that infection was estab-
lished. MAP was detected in the tissue samples from all
but one animal in the infected group (Animal #1,
Table 2A), whereas MAP was not cultured from the
intestinal tissues of the animals from the control group
(Table 2B). Using the phage-PCR method, low numbers
of viable MAP cells were detected in 40 % (6/15; aver-
age number of cells detected = 4.5 per 1 ml blood) of
animals in infected group and none in the control group.
In contrast, the Actiphage method identified detectable
levels of MAP cells in the blood of 87% (13/15) of the
experimentally infected calves. Since the majority of ani-
mal in this group had a confirmed MAP infection, again
this suggests that the Actiphage method is more sensi-
tive than the original phage-PCR method. However,
using the Actiphage method, MAP was also detected in
two of the blood samples from the negative control group
(Table 2, panels A and B). Interestingly, none of the
Table 1. Determining the Limited of detection of the Actiphage assay.
Number of cellsa
MAPb M. bovis BCGb M. bovisb
Phage assay Actiphage method Phage assay Actiphage method Phage assay Actiphage method
104 + + + + + +
103 + + + + + +
102 + + + + + +
101 + + + + + +
100  + + +  +
0      
Results represent the detection of each mycobacteria in three independent samples. For both the phage amplification assay and the Actiphage
method, ‘+’ denotes positive molecular detection in all three replicates;’‘ denotes no detection of mycobacteria in all three replicates.
aNumber of cells added to each sample was determined using the phage amplification enumeration method described by Rees and Botsaris
(2012).
bFor details of the PCR assay used for the different types of bacteria see the method section.
Fig. 2. Comparison of ability of phage-RPA assay and Actiphage
method to detect M. bovis in blood of cattle. Detection of M. bovis
in the blood of cattle stratified by SICCT status and lesion status
(visible lesions; VL, or non-visible lesion, NVL). Phage-positive sam-
ples are in dark grey, and phage-negative samples are in light grey.
The results gained using the Actiphage method are compared with
the previously published results using the phage-RPA assay (Swift
et al., 2016b).
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calves in either the infected or control group showed a
positive response using a commercial Johne’s disease
antibody ELISA test (IDEXX) at necropsy (Table 2).
As the Actiphage method detected MAP from two
samples in the negative control group, a question
remained about the specificity of the Actiphage MAP
assay. Therefore, further testing was carried out using
superfluous DNA samples prepared from the negative
control herd used for the study of SICCT-positive cattle
described in section 3.4 as this herd was also known to
be free of Johne’s disease, as they had not had a positive
Johne’s test animal for at least 5 years. In this case, none
of 45 samples tested gave a positive IS900 PCR result.
Discussion
We have previously described the use of phage amplifi-
cation-PCR or phage-RPA to reduce the time to
detection of viable mycobacteria in blood to 48 h (Swift
et al., 2013); however, this method requires multiple
transfer steps, the incubation of culture plates for 18 h
and manual extraction of DNA from agar, making it
unsuitable for rapid, high-throughput analysis. When
developing the Actiphage assay, some of the principles
of the original phage-PCR assay have been retained.
For example, previous research has shown that using
108 phage per ml in each sample ensures that very low
numbers of mycobacterial cells are productively infected
by the phage. This is simply a probability event of guar-
anteeing two very small particles interact in the (rela-
tively) large sample volume, and at low host cell density,
there is no evidence that this results in lysis from without
or abortive infection (McNerney et al., 2004). The aim of
these experiments was to develop a new, simpler ver-
sion of the phage-PCR amplification assay that was cap-
able of sensitively detecting viable mycobacteria in blood
samples within 1 day. We first stablished the length of
time required for phage D29 to complete its lytic cycle in
different host cells and established that this did result in
release of chromosomal DNA into the phage lysate that
could be used for the detection of signature sequences,
despite the extended incubation period and absence of
agar that might protect the DNA in the original phage-
PCR assay format. However, we also found that carry-
over of intact cells into PCRs can also result in cells lysis,
and release of detectable DNA. Introducing a filtration
step ensured that any unlysed cells present in the sample
did not contaminate the DNA released from the viable
cells so that a positive signal was only achieved when
viable cells were present. Using a combination of phage
lysis with filtration (termed the Actiphage method), limit
of detection studies shows that D29 can be used as an
efficient cell lysis agent that only targets viable cells for a
range of different mycobacterial species. The use of
phage D29 in a closed system means that there is no dri-
ver for phage resistance, which can occur in phage-ther-
apy treatments when the bacteria are continuously
exposed to phage over long periods of time and out-
growth of resistant mutants can occur. The potential limi-
tation exists that the method may not detect phage-
resistant isolates present in blood samples, although
resistance to this particular phage has never been
reported. This could be mitigated against by using cocktail
of phage in these assays. The fact that Actiphage only
detects viable cells ensures that when the bacteria are
detected in blood, we can be confident that an animal is
currently infected, and we are not just detecting free DNA
or the DNA from mycobacteria that may have been killed
by macrophage or detecting an immune response still
present after infection has been controlled.
The method was then applied to two sets of clinical
blood samples, and we could show that it could detect
Table 2. Detection of MAP in experimentally infected calves.
Assigned
number
Phage–PCR assay
MAP
culture
from tissue
No. of
plaquesa
MAP-
PCR
(+/)b
Actiphage-
MAP ELISAc
A
1  1   
2 + 1 + + 
3 + 0 N/A + 
4 + 0 N/A  
5 + 0 N/A + 
6 + 0 N/A + 
7 + 0 N/A + 
8 + 1 + + 
9 + 0 N/A + 
10 + 0 N/A + 
11 + 5 + + 
12 + 15 + + 
13 + 3 + + 
14 + 2  + 
15 + 9 + + 
B
1  11   
2  5   
3  12  + 
4  4   
5  12  + 
6  0 N/A  
7  0 N/A  
8  8   
+, denotes a MAP-positive test result; , denotes a MAP-negative
test result.
aIn the phage-PCR assay, the number of plaques formed is indica-
tive of the number of viable mycobacteria detected; detection of
specific pathogens by the assay is confirmed by PCR.
bSamples are only considered to be MAP-positive in the phage-
PCR assay if IS900 is detected by PCR in DNA extracted from pla-
ques. N/A indicates that no plaques were formed; therefore, the
result was scored as negative (no mycobacteria detected), and
therefore, no PCR was performed.
cIDEXX Johne’s ELISA.
ª 2019 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology., Microbial
Biotechnology, 13, 738–746
742 B. M. C. Swift et al.
viable pathogenic mycobacteria within 6 h. For the sam-
ples from SICCT-positive cattle, we were able to com-
pare the results gained using the Actiphage method
with those reported earlier using the original phage
amplification method. A marked increase in the number
of positive samples detected was seen (39/41 from 27/
41), with all of the VL animals and the majority of the
NVL animals now giving a positive result. Since the
specificity of the SICCT is high [99.91 % (0.013)] for
severe interpretation (Goodchild et al., 2015), there is a
strong probability that these animals were infected with
M. bovis. Two samples did not give a positive results
using Actiphage. Interestingly, these two samples were
also negative in our original study using the original
phage-RPA method and suggest either these animals
had not developed bacteraemia or that the number of
cells in the blood was below the limit of detection of the
assay. The increased number of positive results gained
in the group with known infection increased using the
Actiphage method strongly suggests that, as expected,
the new method is more sensitive than phage-PCR
because the sample material remains in one tube
throughout the test and there is less potential for sample
loss. In contrast, none of the samples from the negative
control group gave a positive result using either method
(n = 45), indicating that the increased sensitivity is not
due to a reduction in test specificity.
The Actiphage method was also shown to be able to
detect MAP in clinical blood samples from experimentally
infected cattle. The results showed that 87 % (13/15) of
experimentally infected animals were infected using the
Actiphage method, and again, the method was more
sensitive than phage-PCR. In this study, the Actiphage
did also detect MAP in two of the negative control group
and there is no obvious explanation for this result. How-
ever, when a further 45 samples from a herd with no his-
tory of MAP infection were tested, all these samples
gave a negative IS900 PCR result, suggesting that these
false-positive results may have occurred due to a partic-
ular circumstance associated with this infection study
rather than due to the specificity of the Actiphage
method when detecting MAP.
The power of this assay is that only the presence of
mycobacteria is needed for Actiphage to give a positive
result, and therefore, it can be applied to any species of
animal as there is no reliance on a host immune
response. Recently, the Actiphage method has been
used to detect M. tuberculosis in the blood of human
patients (Verma et al., 2019). It was also interesting that
in the calf infection study described here, no antibody
response was detected in any of the animals with clear
evidence of systemic infection, although this may reflect
a limitation of the ELISA assays to detect Johne’s dis-
ease as reported by Nielsen and Toft (2008).
Although there are molecular methods capable of
identifying signature DNA from mycobacteria within a
day, the sensitivity of these methods can be compro-
mised by the inefficiency of DNA extraction methods
(Thakur et al., 2011) and most do not distinguish
between live and dead cells, which can result in misin-
terpretation of treatment efficacy and diagnosis (Alli
et al., 2011). Rapid detection of low numbers of viable
slow-growing mycobacteria has generally required ampli-
fication of cell numbers by liquid culture-based methods
or immunomagnetic separation to concentrate cells and
improve subsequent culture (Stewart et al., 2013), but
such methods are still limited by the slow growth of
these bacteria. Reverse transcriptase PCR methods
exist for some mycobacteria but isolation of RNA from
clinical samples is problematic (Alli et al., 2011).
Actiphage offers the potential for rapid, inexpensive,
sensitive detection of live mycobacteria in high-through-
put format that reduces the time to detection of slow-
growing mycobacteria from months to hours. The sensi-
tivity of the method allows detection of low numbers of
cells in clinical blood samples and therefore has the
potential to revolutionize research into mycobacterial
infections.
Experimental procedures
Strains, culture and clinical samples
Laboratory strains of mycobacteria used in this study
were M. smegmatis (mc2155); M. bovis BCG (cv Pas-
teur); M. bovis (clinical badger isolate) MAP strains
K10, ATCC 19698 and B4 (clinical isolate). A low pas-
sage UK MAP field strain (F13) was used for the
experimental calf infections. Both M. bovis (including
BCG) and MAP were cultured and maintained on Mid-
dlebrook 7H11 and 7H10 agar supplemented with
OADC (Becton Dickenson, Swindon, UK), respectively,
and liquid cultures were prepared in Middlebrook 7H9
media supplemented with OADC. All cultures were cul-
tured at 37°C without shaking (to prevent clumping).
M. smegmatis was cultured for up 48 h, M. bovis for
up to 8 weeks and MAP for up to 16 weeks. Liquid cul-
tures of MAP were supplemented with Mycobactin J
(2 µg µl-1; Synbiotics Corporation, Lyon, France). Cul-
tures were confirmed as MAP or M. bovis by end-point
PCR (Techne Thermocycler, Staffordshire, UK) target-
ing IS900 and IS6110 specific genetic elements
respectively. Bacteriophage D29 (supplied by PBD Bio-
tech Ltd, Suffolk, UK) was used to infect the mycobac-
teria. When performing phage assays, Modified 7H9
media was used which consisted of Middlebrook 7H9
media supplemented with 2 mM CaCl2. All cultures
were grown at 37°C without shaking, but with a head
space ratio of at least 1:5.
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Isolation of peripheral blood mononuclear cells (PBMCs)
from clinical samples
For method optimization commercial sheep blood
(Oxoid, UK) was used. Clinical whole blood samples
were obtained after slaughter in Vacutainer sodium-hep-
arin tubes (Becton Dickenson). The isolation of the
PBMCs was carried out using Ficoll-Paque Plus accord-
ing to the manufacturer’s instructions (GE Healthcare
Life Sciences, Amersham, UK). The buffy coat layer was
recovered, and the PBMCs were washed in 6 ml of
PBS, then recovered by centrifugation (100 g, 10 min,
18°C). The PBMC cell pellet was resuspended in modi-
fied 7H9 media (1 ml). These samples were then cen-
trifuged (13 000 g; 3 min), and the bacterial cell pellet
was finally resuspended in modified 7H9 media (100 µl)
prior to performing the Actiphage assay.
Detection and enumeration of mycobacteria and
bacteriophage
Phage D29 suspensions were titred on a lawn of M.
smegmatis grown in soft Middlebrook 7H10 agar (0.75
% w/v) and incubated at 37°C for 18 h. The phage
amplification assay and experimental controls were car-
ried out according to Swift et al., 2016a. Briefly, pro-
cessed blood samples were mixed with 108 D29
bacteriophage to ensure every mycobacteria in the sam-
ple were infected and incubated for 1 h to allow the
phage to infect any mycobacteria present in the sample.
Phage that had not infected their host cells was inacti-
vated using a virucide (ferrous ammonium sulfate;
10 mM final concentration) and the samples were mixed
with approximately 109 M. smegmatis cells and 5 ml
modified 7H9 media before plating using soft 7H10 agar
(0.75 % w/v agar final). The number of mycobacterial
cells detected in the original sample was determined by
counting the number of plaques on the lawn of M. smeg-
matis cells (data reported as pfu ml-1). Enumeration of
mycobacterial cells present in laboratory cultures was
performed using a modification of the phage amplifica-
tion assay which included serial dilution of the samples
prior to plating, and the number of viable mycobacteria
cells detected was reported as pfu ml-1. For detailed
schematics, see Rees and Botsaris (2012).
The length of the eclipse phase for D29 was deter-
mined using a second modification of the phage amplifi-
cation. Briefly, approximately 1 x 102 cells of each host
strain were mixed with phage D29 (m.o.i. 10) and incu-
bated at 37°C for 30 min. Virucide was added to inacti-
vate any free phage, and after 5-min contact time, the
virucide was diluted by the addition of 5 ml of modified
7H9 media. Samples were removed at different time
points and centrifuged (13 000 g; 3 min) to remove
bacterial cells and the number of free phage particles
determine by phage titration on a lawn of M. smegmatis.
Actiphage detection method
For all cattle tested, PBMCs were isolated from whole
blood (Section ‘Determining the Limit of Detection (LOD)
of the Actiphage method in blood’) and were lysed by
resuspending in 100 µl modified 7H9 media. Phage D29
(approximately 107 phage particles in 10 µl) was added to
the sample, giving the same final pfu ml-1 as using in the
original phage amplification assay and incubated for 3 h
at 37°C. After incubation, the samples were filtered at
room temperature using a microcentrifuge tube filter
(0.22 µm pore size, 13 000 g; 3 min). The filtrate was col-
lected and DNA purified and concentrated in 20 µl using
Zymo DNA Clean and Concentrator (Zymo Research,
UK) and used as a template for PCR amplification of sig-
nature sequences (For Schematic see Fig. S2).
Amplification of signature sequences
Purified DNA samples (10 µl) from the phage lysate were
used as template for amplification of signature sequences
using previously published methods. For identification of
mycobacteria from the MTB complex, either amplification
of IS6110 by PCR (Eisenach et al., 1990) or of IS6110
and IS1081 by RPA was used. For the identification of
MAP, IS900 MAP-specific PCR method was used (Slana
et al., 2009). All PCRs were carried out using Hot Start
DNA Polymerase Master Mix Plus (Qiagen, UK).
Sample collection and ethical considerations
The study protocol was approved by the University of
Nottingham, School of Veterinary Medicine and Science
ethical review panel prior to sample usage. Blood sam-
ples from Single Comparative Cervical Intradermal
Tuberculin (SCCIT) reactor cattle were obtained at
slaughter. Blood samples were also obtained from live,
farmed cattle according to the procedures set out in
‘Exceptional private use of non-validated tests for TB on
cattle in England’ Defra TR496 (Rev. 01/18). Blood sam-
ples were obtained from calves experimentally infected
with MAP at the Moredun Research Institute as
described previously (Watkins et al., 2010). The study
design and experimental procedures were assessed and
approved by an Ethics Committee and authorized under
the Animals (Scientific Procedures) Act 1986.
Statistical analysis
Statistical analyses including Pearson’s correlations, t-
tests, sensitivity and specificity data and confidence
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intervals derived from contingency tables were carried
out using Prism 7 (GraphPad, San Diego, CA, USA).
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